questionsmedicales.fr
Personnes
Visiteurs des patients
Visiteurs des patients : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Visiteurs des patients : Questions médicales les plus fréquentes",
"headline": "Visiteurs des patients : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Visiteurs des patients : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-31",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Visiteurs des patients"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Personnes",
"url": "https://questionsmedicales.fr/mesh/D009272",
"about": {
"@type": "MedicalCondition",
"name": "Personnes",
"code": {
"@type": "MedicalCode",
"code": "D009272",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Visiteurs des patients",
"alternateName": "Visitors to Patients",
"code": {
"@type": "MedicalCode",
"code": "D014789",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Samantha J Chiew",
"url": "https://questionsmedicales.fr/author/Samantha%20J%20Chiew",
"affiliation": {
"@type": "Organization",
"name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia."
}
},
{
"@type": "Person",
"name": "Paul H Hemsworth",
"url": "https://questionsmedicales.fr/author/Paul%20H%20Hemsworth",
"affiliation": {
"@type": "Organization",
"name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia."
}
},
{
"@type": "Person",
"name": "Sally L Sherwen",
"url": "https://questionsmedicales.fr/author/Sally%20L%20Sherwen",
"affiliation": {
"@type": "Organization",
"name": "Department of Wildlife Conservation and Science, Zoos Victoria, Parkville, VIC, Australia."
}
},
{
"@type": "Person",
"name": "Grahame J Coleman",
"url": "https://questionsmedicales.fr/author/Grahame%20J%20Coleman",
"affiliation": {
"@type": "Organization",
"name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia."
}
},
{
"@type": "Person",
"name": "Vicky Melfi",
"url": "https://questionsmedicales.fr/author/Vicky%20Melfi",
"affiliation": {
"@type": "Organization",
"name": "Hartpury University and Hartpury College, Gloucester, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.",
"datePublished": "2022-06-29",
"url": "https://questionsmedicales.fr/article/35764767",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10875-022-01308-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling.",
"datePublished": "2022-07-01",
"url": "https://questionsmedicales.fr/article/35776779",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.ppat.1010676"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37096447",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42526"
}
},
{
"@type": "ScholarlyArticle",
"name": "Harnessing type I interferon-mediated immunity to target malignant brain tumors.",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37304294",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1203929"
}
},
{
"@type": "ScholarlyArticle",
"name": "Type I and III interferons are good markers to monitor COVID-19 pathophysiology.",
"datePublished": "2023-03-13",
"url": "https://questionsmedicales.fr/article/36924609",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cyto.2023.156172"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Personnes",
"item": "https://questionsmedicales.fr/mesh/D009272"
},
{
"@type": "ListItem",
"position": 3,
"name": "Visiteurs des patients",
"item": "https://questionsmedicales.fr/mesh/D014789"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Visiteurs des patients - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Visiteurs des patients",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Visiteurs des patients",
"description": "Comment évaluer l'impact des visites sur le patient ?\nQuels signes indiquent qu'un patient a besoin de visites ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Visiteurs des patients",
"description": "Quels symptômes peuvent s'aggraver sans visites ?\nLes visites peuvent-elles réduire la douleur perçue ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Visiteurs des patients",
"description": "Comment prévenir l'isolement des patients ?\nQuelles mesures prendre pour des visites sûres ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Visiteurs des patients",
"description": "Les visites font-elles partie du traitement ?\nComment les hôpitaux gèrent-ils les visites ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Visiteurs des patients",
"description": "Quelles complications peuvent survenir sans visites ?\nLes visites peuvent-elles causer du stress au patient ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Visiteurs des patients",
"description": "Quels facteurs augmentent le besoin de visites ?\nLes patients en soins intensifs ont-ils plus besoin de visites ?",
"url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Interferon+Type+I&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact des visites sur le patient ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact peut être évalué par des questionnaires sur le bien-être et l'état émotionnel."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent qu'un patient a besoin de visites ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un patient peut montrer des signes de solitude, d'anxiété ou de dépression."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent s'aggraver sans visites ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'isolement social peut aggraver l'anxiété et la dépression chez le patient."
}
},
{
"@type": "Question",
"name": "Les visites peuvent-elles réduire la douleur perçue ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le soutien émotionnel des visiteurs peut diminuer la perception de la douleur."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'isolement des patients ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Encourager les visites régulières et utiliser des technologies de communication."
}
},
{
"@type": "Question",
"name": "Quelles mesures prendre pour des visites sûres ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Respecter les protocoles d'hygiène et les restrictions de visite en place."
}
},
{
"@type": "Question",
"name": "Les visites font-elles partie du traitement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les visites peuvent être considérées comme un complément au traitement médical."
}
},
{
"@type": "Question",
"name": "Comment les hôpitaux gèrent-ils les visites ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les hôpitaux établissent des horaires et des règles pour assurer la sécurité des patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir sans visites ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'absence de visites peut entraîner une détérioration de la santé mentale et physique."
}
},
{
"@type": "Question",
"name": "Les visites peuvent-elles causer du stress au patient ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des visites non planifiées ou trop fréquentes peuvent causer du stress."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin de visites ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies chroniques et l'isolement social augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Les patients en soins intensifs ont-ils plus besoin de visites ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients en soins intensifs peuvent bénéficier davantage du soutien des visiteurs."
}
}
]
}
]
}
Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1% of individuals under the age of 60 in the general population, with the prevalence increasing among those over 65. Neu...
Patients who suffered from COVID-19 (n = 622, aged 0-104) and an uninfected healthy control population (n = 3,456, aged 20-91) were enrolled in this study. The severities of the COVID-19 patients were...
In an uninfected general Japanese population aged 20-91, aAbs to IFNs were detected in 0.087% of individuals. By contrast, naAbs to type I IFNs (IFN-α2 and/or IFN-ω, 100 pg/mL) were detected in 10.6% ...
In this study, we revealed that patients with pre-existing naAbs have a much higher risk of life-threatening COVID-19 pneumonia in Japanese population....
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is involved etiologically in AIDS-associated KS, primary effusion lymphoma (PEL), and multicentric Castleman's ...
The type 1 interferon (IFN) pathway is up-regulated in dermatomyositis (DM). We sought to define how organ-specific disease activity as well as autoantibodies and other clinical factors are independen...
RNA sequencing was performed on 355 whole blood samples collected from 202 well-phenotyped DM patients followed up during the course of their clinical care. A previously defined 13-gene type I IFN sco...
The pattern of type I IFN-driven transcriptional response was stereotyped across samples with a sequential modular activation pattern strikingly similar to systemic lupus erythematosus. The median typ...
The type I IFN score is independently associated with skin and muscle disease activity as well as certain clinical and serologic features in DM. Accounting for the effect of muscle disease and anti-MD...
Type I interferons have long been appreciated as a cytokine family that regulates antiviral immunity. Recently, their role in eliciting antitumor immune responses has gained increasing attention. With...
The COVID-19 pandemic has caused millions of deaths and has resulted in disastrous societal and economic impacts worldwide. During SARS-CoV-2 infection, abnormal levels of pro-inflammatory cytokines h...
The tumor microenvironment consists of tumor cells, extracellular matrix, blood vessels, and non-tumor cells such as fibroblasts and immune cells. Crosstalk among components of this cellular ecosystem...
Autoimmune polyendocrine syndrome type I (APS-1) is caused by mutations in the autoimmune regulator (AIRE) gene and characterised clinically by multiple autoimmune manifestations and serologically by ...
Rotavirus infects intestinal epithelial cells and is the leading cause of gastroenteritis in infants worldwide. Upon viral infection, intestinal cells produce type I and type III interferons (IFNs) to...
Presence of autoantibodies targeting nuclear constituents, i.e., double-stranded DNA and small nuclear ribonucleoproteins (snRNPs), remain a cornerstone in systemic lupus erythematosus (SLE). Fcγ rece...
Type I interferon (IFN) signalling is tightly controlled. Upon recognition of DNA by cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) translocates along the endoplasmic reticulum...